Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
about
Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-effectiveness of gefitini ...... all cell lung cancer in China.
@en
Cost-effectiveness of gefitini ...... all cell lung cancer in China.
@nl
type
label
Cost-effectiveness of gefitini ...... all cell lung cancer in China.
@en
Cost-effectiveness of gefitini ...... all cell lung cancer in China.
@nl
prefLabel
Cost-effectiveness of gefitini ...... all cell lung cancer in China.
@en
Cost-effectiveness of gefitini ...... all cell lung cancer in China.
@nl
P2093
P2860
P356
P1433
P1476
Cost-effectiveness of gefitini ...... all cell lung cancer in China.
@en
P2093
P2860
P304
9996-10006
P356
10.18632/ONCOTARGET.14310
P407
P577
2016-12-27T00:00:00Z